Orchid Pharma Limited
Orchid Pharma Limited, a pharmaceutical company, engages in the development, manufacture, and marketing of active pharmaceutical ingredients, bulk actives, finished dosage formulations, and nutraceuticals in India. Its active pharmaceutical ingredients product portfolio includes oral cephalosporins, injectable cephalosporins; human and veterinary products; and antibiotics, including betalactam, macrolide, fluoroquinolone, and imidazole. The company also exports its products to approximately 40 countries internationally. The company was formerly known as Orchid Chemicals & Pharmaceuticals Limited and changed its name to Orchid Pharma Limited in October 2015. Orchid Pharma Limited was incorporated in 1992 and is headquartered in Chennai, India. Orchid Pharma Limited operates as a subsidiary of Dhanuka Laboratories Limited.
Valuation
Profitability
Returns
Solvency
AI Summary
Indian StockStrengths1
- Revenue grew 12.6% YoY
Concerns1
- Negative free cash flow (βΉ18 Cr)
Rule-based from financial data. Not advice.
Monthly Returns
Year-to-Date ROI
Historical Volatility
Historical Performance
Revenue, profitability, and cash flow trends (βΉ Crores)
Revenue (10Y)
Operating Income (10Y)
Net Profit (10Y)
Operating Margin % (10Y)
Dividend Payout % (10Y)
Free Cash Flow (10Y)
Growth Summary
Latest fiscal year: Mar 2025
Historical Growth
Year-by-year revenue, profitability, and cash flow (βΉ Crores, last 10 years)
| Year | Revenue | Op. Income | Net Profit | CFO | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|---|
| Mar 2025 | βΉ922.00 Cr | β | βΉ106.00 Cr | β | β | β | 12.6% | 11.6% |
| Mar 2024 | βΉ819.00 Cr | β | βΉ95.00 Cr | β | β | β | 23.0% | 75.9% |
| Mar 2023 | βΉ666.00 Cr | β | βΉ54.00 Cr | β | β | β | 19.6% | -1180.0% |
| Mar 2022 | βΉ557.00 Cr | β | βΉ-5.00 | β | β | β | 23.5% | -95.7% |
| Mar 2021 | βΉ451.00 Cr | β | βΉ-117.00 | β | β | β | -6.2% | -22.0% |
| Mar 2020 | βΉ481.00 Cr | β | βΉ-150.00 | β | β | β | -17.6% | 48.5% |
| Mar 2019 | βΉ584.00 Cr | β | βΉ-101.00 | β | β | β | -9.3% | -71.5% |
| Mar 2018 | βΉ644.00 Cr | β | βΉ-355.00 | β | β | β | -14.7% | -27.4% |
| Mar 2017 | βΉ755.00 Cr | β | βΉ-489.00 | β | β | β | -14.1% | 78.5% |
| Mar 2016 | βΉ879.00 Cr | β | βΉ-274.00 | β | β | β | -49.4% | 43.5% |
Financial Statements
Income statement, balance sheet, and cash flow (βΉ Crores, as reported)
Consolidated Figures in USD Millions.
| Unnamed: 0 | TTM |
|---|---|
| Revenue / Net Sales | 811 |
| Total Expenses | 761 |
| EBIT / Operating Profit | 51 |
| OPM % | 6 |
| Other Income | 41 |
| Finance Costs | 14 |
| Depreciation & Amortisation | 35 |
| Profit Before Tax | 42 |
| Tax % | - |
| Net Profit / PAT | 42 |
| EPS (βΉ) | 8.37 |
| Dividend Payout % | - |
Peer Comparison
Healthcare sector peers, ranked by market cap
| Company | Market Cap | Revenue | P/E | P/B | EV/EBITDA | Rev G 1Y |
|---|---|---|---|---|---|---|
| Orchid Pharma Limitedthis co. | βΉ3.74 K Cr | βΉ922.00 Cr | 51.80 | 2.78 | 0.00 | 12.6% |
| Sun Pharmaceutical Industries Ltd. | βΉ4.15 L Cr | βΉ23.00 K Cr | 88.70 | 17.43 | 72.30 | 13.5% |
| Divi's Laboratories Ltd. | βΉ1.71 L Cr | βΉ9.20 K Cr | 67.90 | 11.13 | 67.21 | 20.0% |
| Torrent Pharmaceuticals Ltd. | βΉ1.33 L Cr | βΉ9.68 K Cr | 62.50 | 15.76 | 45.64 | 13.5% |
| Cipla Ltd. | βΉ1.17 L Cr | βΉ19.05 K Cr | 22.50 | 3.51 | 19.33 | 14.9% |
| Apollo Hospitals Enterprises Ltd. | βΉ1.05 L Cr | βΉ8.20 K Cr | 75.00 | 11.28 | 54.44 | 12.8% |
| Max Healthcare Institute Limited | βΉ1.00 L Cr | βΉ2.66 K Cr | 144.00 | 11.76 | 96.84 | 13.8% |
| Industry Average | β | βΉ3.29 K Cr | 98.63 | 8.11 | 65.50 | 20.2% |